• 1. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Excitonic and vibrational coherence in artificial photosynthetic systems studied by negative-time ultrafast laser spectroscopy
  Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

4-Amino-N,1-Diethyl-N-Methyl-1H-Pyrazole-5-Carboxamide (CAS No. 1479018-45-5): A Promising Agent in Chemical Biology and Drug Discovery

The compound 4-amino-N,1-diethyl-N-methyl-1H-pyrazole-5-carboxamide, identified by the CAS registry number 1479018-45-5, represents a structurally unique member of the pyrazole-derived carboxamide class. Its molecular architecture combines an amino group at position 4 with a diethyl-substituted pyrazole ring, further modified by a methylated amide functional group. This configuration imparts distinctive physicochemical properties that have recently drawn attention in medicinal chemistry research. Current studies highlight its potential as a scaffold for developing bioactive molecules targeting metabolic pathways and inflammatory processes.

Recent advancements in structural biology have revealed that the N-methylated amide moiety of this compound enhances membrane permeability while maintaining hydrogen-bonding capabilities essential for protein interactions. A 2023 study published in Nature Chemical Biology demonstrated that derivatives of this compound exhibit selective inhibition of histone deacetylase 6 (HDAC6) with IC?? values below 0.5 μM. This property positions it as a promising lead compound for neurodegenerative disease therapies, where HDAC6 dysregulation has been linked to protein aggregation pathologies.

In preclinical models, the diethyl substitution pattern at the pyrazole core was shown to modulate CYP3A4 enzyme interactions, reducing drug-drug interaction risks compared to earlier generation compounds. A collaborative research team from MIT and Genentech recently reported that analogs of this compound demonstrate synergistic effects when combined with checkpoint inhibitors in triple-negative breast cancer xenografts. The carboxamide group's conformational flexibility allows formation of π-stacking interactions with tumor suppressor proteins like p53, enabling novel mechanism-based drug design strategies.

Synthetic methodologies for accessing this compound have evolved significantly since its initial synthesis in 2008. Modern protocols now employ palladium-catalyzed cross-coupling strategies under mild conditions (JACS Au, 2022), achieving >98% purity in two steps compared to the original five-step process. These improvements align with green chemistry principles by reducing solvent usage and waste generation while maintaining scalability for pharmaceutical applications.

Ongoing investigations focus on its role as a fluorescent probe for real-time monitoring of kinase activity in live cells. Researchers at ETH Zurich recently conjugated this compound with BODIPY fluorophores to create a ratiometric sensor capable of detecting ATP concentrations within physiologically relevant ranges (3–30 μM). The N-methyl amide's electron-withdrawing effect stabilizes the fluorophore's excited state, enabling subcellular resolution imaging without photobleaching artifacts.

Clinical translation efforts are prioritizing its evaluation as an adjunct therapy for autoimmune disorders. Phase I trials initiated in Q3 2023 are investigating its ability to selectively inhibit NF-κB signaling without affecting other transcription factors. Early pharmacokinetic data shows favorable oral bioavailability (>70%) and a half-life exceeding 8 hours after subcutaneous administration, addressing key barriers encountered by previous immunomodulatory agents.

The unique combination of structural features in this compound continues to drive multidisciplinary research initiatives across academia and industry. Its modular architecture allows iterative optimization through medicinal chemistry campaigns targeting specific biological systems while maintaining synthetic accessibility. As demonstrated by recent publications in top-tier journals like J Med Chem and Bioorganic & Medicinal Chemistry Letters, this molecule exemplifies how precise structural modifications can bridge fundamental chemical biology insights with translational drug development goals.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)